Pharmaceutical Industry in the
Canton of Schwyz
69 companies in Pharmaceutical Industry based in the Canton of Schwyz — name and year of registration from the commercial register.
50 of 69 companies
Schwabe Pharma AG
Since 1992 · 51–100 empl.
The company's core activity is the production and distribution of homeopathic and herbal remedies.
Octapharma AG
Since 1999 · 101–500 empl.
The core activity of Octapharma is the development, production and marketing of healthcare solutions, in particular plasma-based medicines that improve patients' lives. This includes plasma collection, research and development of therapeutic proteins, production of medicines and clinical testing of products. The company operates its own plasma donation centers and invests in expanding its network to ensure the availability of plasma.
Swyssi PMFS AG
Since 2000 · 11–20 empl.
The core activity of Swyssi is the development and manufacture of complex generic drugs, as well as the life cycle extension of established, off-patent medicines, particularly in the areas of cardiology, diabetes, central nervous system and respiratory diseases.
adastra AG
Since 2004 · 1–10 empl.
adastra AG is a floorball club with men’s and youth teams. The club runs competitive and development programs, supports junior players, and provides services for members, volunteers, and sponsors.
Shield TX (Switzerland) AG
Since 2009 · 51–100 empl.
The core activity of Shield Therapeutics plc is the development and marketing of specialized pharmaceuticals, particularly for the treatment of iron deficiency, including anemia. The company focuses on developing medications that improve the lives of people with iron deficiency and has already developed a leading product called ACCRUFeR®, which is approved for the treatment of iron deficiency in adults.
PhytoNet AG
Since 2009 · 51–100 empl.
The core activity of Phytonet is the development, manufacture and distribution of health products, particularly in two main areas: 1. **Health Ingredients Division**: Phytonet distributes health ingredients and innovative dietary supplements. 2. **Pharmaceutical Division**: The company develops and manufactures finished pharmaceutical formulations. Phytonet positions itself as a provider of health solutions, ranging from the procurement of raw materials to the production of finished products.
EffRx Pharmaceuticals SA
Since 2009 · 11–20 empl.
The core activity of EffRx Pharmaceuticals SA is the development, approval and marketing of medicines for rare and niche diseases in Europe and Switzerland. The company focuses particularly on the late-stage development and market entry of therapeutics for patients with rare diseases such as osteoporosis, adrenal insufficiency, congenital adrenal hyperplasia and Niemann-Pick disease. EffRx works closely with partners to develop and bring new medicines to market, offering accelerated decision-making processes and rapid market entry for its customers.
Benemedo GmbH
Since 2010 · 11–20 empl.
Benemedo GmbH is a pharmaceutical and cosmetics company specializing in the development, manufacture and marketing of its own product lines. The company's core activity encompasses the production and distribution of pharmaceuticals and cosmetics, particularly under the brands Vitella, Mediket, Benevet and Benemedio. The company works closely with partners from the pharmaceutical industry and has a strong presence in Europe, North America and Asia.
Swiss-Canna Group AG
Since 2012 · 1–10 empl.
The core activity of Swiss-Canna Group AG is the development and manufacture of CBD-based, non-prescription health products based on scientific principles, combining natural principles and state-of-the-art technology. The company focuses on creating premium natural products that offer the highest product quality, maximum effectiveness and consistent customer orientation.
HISTIDE AG
Since 2014 · 21–50 empl.
The core activity of Histide AG is the development and marketing of biotechnological products, in particular so-called Cell Recoding Molecules (CRM), which are intended for the treatment of rare diseases and tissue regeneration. The company focuses on the research and development of non-mutagenic extracellular therapeutic agents and has a strong patent and technology platform.
Hempcare GmbH
Since 2018 · 11–20 empl.
The core activity of Swiss HempCare is the production and distribution of products made from the medicinal plant Cannabis Sativa L., particularly CBD products. The company focuses on the development and production of high-quality core products tailored to the needs of its customers.
Somagenetix AG
Since 2019 · 11–20 empl.
The core activity of Somagenetix AG is the development and research of gene therapies for genetic diseases, particularly for phagocytic disorders such as chronic granulomatous disease (CGD). The company focuses on the development of lentivirus-mediated gene therapies that are designed to offer a unique combination of safety, specificity and long-term efficacy.
MediCrops AG
Since 2019 · 51–100 empl.
The core activity of MediCrops AG is the development and provision of medical cannabis products and therapies. The company focuses on researching and developing innovative products that meet the needs of patients, and aims to revolutionize patient care by optimizing cannabis therapies.
Salus Schweiz AG
Since 2020 · 11–20 empl.
The core activity of Salus Schweiz AG is the development, manufacture and distribution of health products, in particular tonics, teas, elixirs, tablets and other plant-based products.
IDEOGEN AG
Since 2013 · 21–50 empl.4.0(4)
IDEOGEN AG is a pharmaceutical services company that partners with biotech and pharmaceutical organisations to enable access to specialty therapeutics and provide commercial and medical support. Its services include managed-access and early-access programmes, supply and distribution for licensed and unlicensed medicines, pharmacovigilance, and research & development support.
DiNAQOR AG
Since 2024 · 21–50 empl.
DiNAQOR AG is a biotechnology company builder that develops platform technologies and launches focused companies in tissue science, precision medicine and genetic therapies. Its portfolio includes entities such as DiNATEQ, DiNAMIQS, DiNABiOS and DAiNA; the group provides access to GMP‑compliant viral vector manufacturing and advances precision gene‑therapy programs for cardiomyopathies, heart failure and polycystic kidney disease.
Delta4 AG
Since 2023 · 11–20 empl.
Delta4 AG is a TechBio company that applies AI, systems biology and computational modeling to discover new indications for drugs with established safety profiles. The company operates the Hyper‑C platform and provides in‑silico models, indication‑expansion services and partnering for drug development.
MABEWO PHYTOPHARM AG
Since 2020 · 1–10 empl.4.1(9)
MABEWO PHYTOPHARM AG develops and sells technologies and services for the automated production of medicinal plants. The company designs and constructs modular, scalable systems for controlled‑environment cultivation (GACP room construction), emphasizing reproducible quality, regulatory compliance and the integration of renewable energy and efficient processes.
pharma services Oehler GmbH
Since 2006 · 11–20 empl.5.0(2)
pharma services Oehler GmbH provides pharmaceutical services in quality assurance, regulatory affairs and pharmacovigilance, including preparation of eCTD and other regulatory submission dossiers. The company also advises on food, cosmetic and medical-device related matters and supports market entry into Switzerland.
Path Pharma GmbH
Since 2023 · 11–20 empl.
Path Pharma GmbH is a pharmaceutical company specializing in the development, manufacture, and marketing of medicines and health products for rare diseases and oncology/hematology. The company's core activity involves providing medical products, services, and support programs for patients, caregivers, and healthcare professionals in this field. This includes the development and marketing of medicines, provision of patient support programs, conducting medical research, and collaboration with health organizations and authorities.
Mera Pharma GmbH
Since 2012 · 11–20 empl.5.0(3)
The company's core activity is the development and manufacture of products in various industries, particularly in the pharmaceutical industry, the cosmetics and dietary supplements industry. The company focuses on implementing customer ideas into innovative, high-quality end products and works with leading manufacturers in Europe to utilize the latest technologies and expertise.
IDEOGEN GROUP GmbH
Since 2021 · 21–50 empl.4.0(4)
IDEOGEN GROUP GmbH is a family-owned Swiss pharmaceutical group that facilitates access to specialty medicines for unmet medical needs. The company provides commercialization and distribution of licensed and unlicensed products, manages early-access and named‑patient programs, and delivers regulatory, pharmacovigilance and operational services including GMP/GDP and wholesale distribution capabilities.
Saiba X AG
Since 2024 · 1–10 empl.
Saiba X AG develops vaccines and virus-like particle technologies for use against chronic and infectious diseases. The company also provides consulting, licensing and development services for vaccine projects.
Cantreat AG
Since 2023 · 11–20 empl.4.0(1)
The core activity of Cantreat AG is the development and marketing of innovative products for cancer treatment, particularly through the development of nanoparticles for targeted drug delivery in tumor types that are difficult to operate on or where operations have far-reaching consequences for the patient.
CellShield AG
Since 2019 · 1–10 empl.
CellShield AG is an investment-focused company that manages capital allocation, supports revenue-generating projects and aims to secure returns.
TACHRIS AG
Since 2008 · 1–10 empl.
Pharmacon AG
Since 2013 · 1–10 empl.
Pharmacon AG is a company whose website provides contact details but no information about products, services, or business activities. The site only shows the company name, address, phone number, and email address.
Focus Health AG
Since 1965 · 1–10 empl.
Matterhorn AG, Pharmazeutica
Since 1986 · 1–10 empl.
Pharma Globe AG
Since 1994 · 1–10 empl.
NCC Nutrition Care Company AG
Since 2000 · 1–10 empl.
athenstaedt AG
Since 2001 · 1–10 empl.
EuroPharma GmbH
Since 2001 · 1–10 empl.
Sedapharm AG
Since 2004 · 1–10 empl.
Phoenux AG
Since 2005 · 1–10 empl.
GENERA PHARMA AG
Since 2005 · 1–10 empl.
Dicon AG
Since 2006 · 1–10 empl.
Alembic Global Holding SA
Since 2007 · 1–10 empl.
Castiglione Medica GmbH
Since 2009 · 1–10 empl.
Mind-NRG Sàrl
Since 2010 · 1–10 empl.
HealVax GmbH
Since 2011 · 1–10 empl.
Santis Pharma AG
Since 2011 · 1–10 empl.
Burgerstein Apotheke AG
Since 2014 · 1–10 empl.
Shiva Pharmachem SA
Since 2014 · 1–10 empl.
Pharmafox Therapeutics AG
Since 2014 · 1–10 empl.
Medicalsanomed AG
Since 2015 · 1–10 empl.
Swiss Nutri GmbH
Since 2016 · 1–10 empl.
Pharmaprint GmbH
Since 2018 · 1–10 empl.
New Horizon Global GmbH
Since 2018 · 1–10 empl.
GxP-Agentur GmbH
Since 2019 · 1–10 empl.
Pharmaceutical Industry in the Canton of Schwyz
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Pharmaceutical Industry in other places
By canton